↓ Skip to main content

Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung…

Overview of attention for article published in BMC Cancer, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
Published in
BMC Cancer, August 2015
DOI 10.1186/s12885-015-1593-2
Pubmed ID
Authors

Yuichi Ozawa, Minako Omae, Masato Fujii, Takashi Matsui, Masato Kato, Shinya Sagisaka, Kazuhiro Asada, Masato Karayama, Toshihiro Shirai, Kazumasa Yasuda, Yutaro Nakamura, Naoki Inui, Kazunari Yamada, Koshi Yokomura, Takafumi Suda

Abstract

Magnetic resonance imaging (MRI) enables a more sensitive detection of brain metastasis and stereotactic irradiation (SRI) efficiently controls brain metastasis. In limited-stage small cell lung cancer (LS-SCLC), prophylactic cranial irradiation (PCI) in patients with good responses to initial treatment is recommended based on the survival benefit shown in previous clinical trials. However, none of these trials evaluated PCI effects using the management of brain metastasis with MRI or SRI. This study aimed to determine the effects of MRI and SRI on the benefits of PCI in patients with LS-SCLC. The clinical records of pathologically proven SCLC from January 2006 to June 2013 in facilities equipped with or had access to SRI in Japan were retrospectively reviewed. Patients with LS-SCLC and complete or good partial responses after initial treatment were included in the study and analyzed by the Kaplan-Meier method. Of 418 patients with SCLC, 124 met criteria and were divided into patients receiving PCI (PCI group; n = 29) and those without PCI (non-PCI groups; n = 95). At baseline, ratios of patients with stage III were significantly advantageous for the non-PCI group, although younger age and high ratios of complete response and MRI confirmed absence of brain metastasis were advantageous for the PCI group. Neither median survival times (25 vs. 34 months; p = 0.256) nor cumulative incidence of brain metastasis during 2 years (45.5 vs. 30.8 %; p = 0.313) significantly differed between the two groups. Moreover, these factors did not significantly differ among patients with stage III disease (25 vs. 26 months; p = 0.680, 42.3 vs. 52.3 %; p = 0.458, respectively). PCI may be less beneficial in patients with LS-SCLC if the management with MRI and SRI is available.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 3%
Unknown 37 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 16%
Student > Ph. D. Student 4 11%
Student > Master 4 11%
Other 2 5%
Student > Bachelor 2 5%
Other 5 13%
Unknown 15 39%
Readers by discipline Count As %
Medicine and Dentistry 16 42%
Nursing and Health Professions 2 5%
Biochemistry, Genetics and Molecular Biology 1 3%
Social Sciences 1 3%
Physics and Astronomy 1 3%
Other 0 0%
Unknown 17 45%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2016.
All research outputs
#5,674,709
of 7,849,747 outputs
Outputs from BMC Cancer
#1,884
of 3,368 outputs
Outputs of similar age
#142,987
of 227,458 outputs
Outputs of similar age from BMC Cancer
#88
of 144 outputs
Altmetric has tracked 7,849,747 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,368 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,458 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 144 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.